Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis

Mercado, Ulises; Acosta, Héctor; Díaz-Molina, Raúl

doi:10.3899/jrheum.081227

Cited by 15 publications

(7 citation statements)

References 5 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence strongly supported the safety and immunogenicity of TT vaccination in juvenile SLE and JIA patients, even when using immunosuppressive drugs 45 94 95. Most studies supported the safety and immunogenicity of diphtheria,95 Hib,96 97 HAV,98 HBV,26 53 98–102 PPV,27 51 52 54 103–106 pneumococcal conjugate16 53 and meningococcal conjugate vaccines 107. Four SLE flares were described after polio vaccination in a retrospective analysis 10.…”

Section: Resultsmentioning

confidence: 96%

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

et al. 2011

View full text Add to dashboard Cite

Evidence-based recommendations for vaccination of paediatric patients with rheumatic diseases (PaedRD) were developed by following the EULAR standardised procedures for guideline development. The EULAR task force consisted of (paediatric) rheumatologists/immunologists, one expert in vaccine evaluation, one expert in public health and infectious disease control, and one epidemiologist. A systematic literature review was conducted in MEDLINE, EMBASE, and abstracts of the EULAR and American College of Rheumatology meetings of 2008/9. The level of evidence and strength of recommendation were based on customary scoring systems. Delphi voting was applied to assess the level of agreement between task force members. 107 papers and eight abstracts were used. The majority of papers considered seasonal influenza (41) or pneumococcal (23) vaccination. 26 studies were performed specifically in paediatric patients, and the majority in adult rheumatoid arthritis and systemic lupus erythematosus patients. Fifteen recommendations were developed with an overall agreement of 91.7%. More research is needed on the safety and immunogenicity of (live-attenuated) vaccination in PaedRD, particularly in those using biologicals, and the effect of vaccination on prevention of infections.

show abstract

Section: Resultsmentioning

confidence: 96%

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

et al. 2011

View full text Add to dashboard Cite

show abstract

“…There are limited data on the more potent immunosuppressant, cyclophosphamide, in rheumatic diseases. The response to PPSV-23 in two patients with systemic sclerosis on cyclophosphamide was severely impaired [ 36 ].…”

Section: Resultsmentioning

confidence: 99%

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

Bingham

2014

Arthritis Res Ther

View full text Add to dashboard Cite

Vaccinations are administered to patients to induce a protective immune response, resulting in immunological memory. Preventing infection through the use of vaccines is particularly important in immunocompromised and immunosuppressed individuals given their increased frequency and severity of infections relative to healthy individuals. Recent surveys show that the vaccination rate is still alarmingly low in patients with rheumatic disease. In this review we briefly discuss the different types of vaccines and then critically examine evidence related to vaccination efficacy in patients with autoimmune disease and the effects of immunomodulatory therapy, with an aim to provide guidance and optimize the administration of vaccines in such individuals.

show abstract

“…117,118 In 15 of 18 patients with systemic sclerosis, pneumococcal vaccination resulted in an anti-pneumococcal antibody titre considered protective for ≥3 of 4 tested serotypes. 119 …”

Section: Reviewsmentioning

confidence: 97%

Vaccination of patients with autoimmune inflammatory rheumatic diseases

et al. 2014

View full text Add to dashboard Cite

Patients with autoimmune inflammatory rheumatic diseases (AIRDs) are at increased risk of infections. This risk has been further increased by the introduction of biologic agents over the past two decades. One of the most effective strategies to prevent infection is vaccination. However, patients with an AIRD have a compromised immune system, which is further impaired by medication. Another important issue is the possibility of triggering a broad nonspecific response by vaccination, potentially resulting in increased activity of the underlying autoimmune disease. In this Review, we provide an analysis of data on vaccination of patients with an AIRD. Both the efficacy and the safety of vaccination are addressed, together with the epidemiology of vaccine-preventable infectious diseases in different subgroups of adults with AIRDs. Special attention is given to vaccination of patients who are treated with biologic agents.

show abstract

Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis

Cited by 15 publications

References 5 publications

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

EULAR recommendations for vaccination in paediatric patients with rheumatic diseases

Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases

Vaccination of patients with autoimmune inflammatory rheumatic diseases

Contact Info

Product

Resources

About